Edesa Biotech's Paridiprubart Shows Promise in Inhibiting Inflammation from Influenza and Other Pathogens

Edesa Biotech, Inc. announced positive findings from an in vitro study of its monoclonal antibody candidate, paridiprubart, against a panel of respiratory pathogens. The study demonstrated that inflammation signaling from multiple pathogens, including Influenza A, coronavirus, and a common bacterium (H. influenzae), was inhibited by Edesa's TLR4 antagonist, paridiprubart. These findings support ..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 29.
  • textsms

GSK Shares Positive Data for AREXVY, its Respiratory Syncytial Virus (RSV) Older Adult Vaccine, Indicating Protection Over Two RSV Seasons

GSK has announced positive results from its clinical trial of AREXVY, a vaccine for respiratory syncytial virus (RSV) in older adults. The AReSVi-006 phase III trial found that the vaccine provided protection against RSV-lower respiratory tract disease and severe disease over two full RSV seasons, including in participants with underlying medical conditions. Safety and reactogenicity data were c..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 22.
  • textsms